The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptor
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Prostate cancer is the second most common male malignancy in the western world an increasing incidence in an ageing population. Treatment of advanced prostate cancer relies on androgen deprivation. Although the majority of patients initially respond favourably to androgen deprivation therapy, the mean time to relapse is 12-18 months. Currently there are few treatments available for men who \nhave developed resistance to hormone therapy, due to the lack of understanding of the molecular mechanisms underlying development of this disease. Recently, however, major advances have been made in understanding both \nandrogen receptor (AR) dependent and independent pathways which promote development of hormone resistant prostate cancer. This review will focus on modifications to the AR and associated pathways. Molecular modifications to the \nandrogen receptor itself, e.g. mutations and/or amplification, although involved in the development of hormone resistance cannot explain all cases. Phosphorylation of AR, via either Ras/MAP kinase or PI3K/Akt signal transduction pathways, have been shown to activate AR in both a ligand (androgen) dependent and independent fashion. During this review we will discuss the clinical evidence to support AR dependent pathways as mediators of hormone resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Nuclear receptors: integration of multiple signalling pathways through phosphorylation
Rochette-Egly, C. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00115-8 · Cited by 291
Cited by
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Morgan, T., Koreckij, T., & Corey, E. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787580999 · Cited by 283
Alimirah, F., Chen, J., Basrawala, Z., Xin, H., & Choubey, D. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.041 · Cited by 265
Zoubeidi, A., Zardan, A., Beraldi, E., Fazli, L., Sowery, R., Rennie, P., Nelson, C., & Gleave, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2057 · Cited by 256
Regulation of the androgen receptor by SET9-mediated methylation.
Gaughan, L., Stockley, J., Wang, N., McCracken, S. R. C., Treumann, A., Armstrong, K., Shaheen, F., Watt, K., McEwan, I. J., Wang, C., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq861 · Cited by 127
“To address if the interaction between AR and SET9 was direct, we immunoprecipitated purified His-tagged SET9 using an anti-SET9 antibody from a mixture containing either His-tagged N-terminal transactivation domain (AR-TD) (40) or His-tagged DNA-binding domain (DBD)/hinge domain (H)/ligand-binding domain (LBD) (AR-DBD…”
BackgroundInfluentialAndrogen regulation of gene expression.
(2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07005-3 · Cited by 117
Metadata
- Authors
- Edwards, J., & Bartlett, J. M. S.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2005-05-12
- Volume
- 95
- Issue
- 9
- Pages
- 1320-1326
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2068319312
- Cited by
- 143
- References
- 3
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptor. https://app.cochat.ai/papers/10.1111/j.1464-410x.2005.05526.x
- The paper
- Edwards, J., & Bartlett, J. M. S. (2005). The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU International. https://doi.org/10.1111/j.1464-410x.2005.05526.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.